Who is sponsoring NCT03496506?

NCT03496506 is sponsored by Actelion.

What condition does NCT03496506 study?

NCT03496506 studies Healthy Subjects.

What drugs are being tested in NCT03496506?

Interventions: Selexipag, Clopidogrel.

What is the status of NCT03496506?

NCT03496506 is currently COMPLETED.

Last reviewed 2025-06-22 · How we verify

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

NCT03496506 PHASE1 COMPLETED

The purpose of this study is to evaluate the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite (ACT-333679) in healthy male adults (by determining the blood concentrations of selexipag and its metabolite). Also, the safety of selexipag when administered alone or with clopidogrel will be assessed.

Details

Lead sponsor	Actelion
Phase	PHASE1
Status	COMPLETED
Enrolment	22
Start date	Mon Mar 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy Subjects

Interventions

Selexipag
Clopidogrel

Countries

Belgium